Special Issue "Glycomics in Drug Discovery"
Deadline for manuscript submissions: closed (26 June 2022) | Viewed by 398
The journal Pharmaceuticals is preparing a Special Edition entitled “Glycomics in Drug Discovery”. This edition will focus on the role glycomics plays in disease discovery and development of therapeutics. The aim is to cover many different aspects of glycomics beginning with the technology employed in glycomic research through to the use of glycomics as biomarkers, glycomics as drug targets, and finally the role of glycomics in various pathologies (e.g., oncology, neurology, etc.). Please let me know if you are interested in submitting an article and I will work directly with you to make the process as enjoyable as possible!
Glycosylation of proteins, in particular, represent one of the most common types of post-translational modifications (PTMs). Much like phosphorylation, glycans contribute to the overall function of the protein, lipid, or other biological molecule to which they are attached. These glycans have been shown to play a role in a variety of diseases including cancer, cardiovascular, neurological, and diabetes. While these modifications vary during disease progression, their complexity and diversity makes characterizing their molecular structure a challenge. Glycomics, dedicated to research focused on glycans, covers the characterization of the glycan groups present within a cell or an organism. As glycomic technologies increase in capability, researchers have been able to begin to unravel how glycosylation effects disease progression. In addition, unique glycosylation signatures associated with specific diseases are beginning to be recognized. In this special edition, we present a series of articles that review the various technologies used in glycomics to identify unique glycan signatures within cells. In addition, the use of these glycan signatures to identify specific diseases and development therapeutic options is described. Indeed, glycomics represents a vast opportunity to discover novel biomarkers and therapeutic targets for a variety of pathologies.
Dr. Timothy D. Veenstra
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug discovery, biomarkers
- cancer diagnosis, neurology